



HOKKAIDO UNIVERSITY

Title	Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
Author(s)	Shimizu, Tomohiro; Arita, Kosuke; Murota, Eihiro et al.
Citation	Journal of Bone and Mineral Metabolism, 39(5), 868-875 https://doi.org/10.1007/s00774-021-01226-1
Issue Date	2021-09
Doc URL	https://hdl.handle.net/2115/86683
Rights	This is a post-peer-review, pre-copyedit version of an article published in Journal of Bone and Mineral Metabolism. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00774-021-01226-1
Type	journal article
File Information	J Bone Miner Metab 39 868-875.pdf



**Effects after starting or switching from bisphosphonate to romosozumab or denosumab in
Japanese postmenopausal patients**

Tomohiro Shimizu^{1*,#}, Kosuke Arita^{1,#}, Eihiro Murota², Shigeto Hiratsuka^{1,2}, Ryo Fujita^{1,3},
Hotaka Ishizu¹, Tsuyoshi Asano¹, Daisuke Takahashi¹, Masahiko Takahata¹, Norimasa Iwasaki¹

¹ Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine,
Hokkaido University, Sapporo, Japan

² Department of Orthopaedic Surgery, Wajyokai Sapporo Hospital, Sapporo, Japan

³ Department of Orthopaedic Surgery, Hokkaido Orthopaedic Memorial Hospital, Sapporo,
Japan

*Correspondence:

Tomohiro Shimizu

Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine,
Hokkaido University, Sapporo, Hokkaido, Japan

Kita-15 Nishi-7, Kita-ku, Sapporo, 060-8638, Japan

Phone: +81-11-716-1161 ext. 5936, Fax +81-11-706-6054

E-mail: simitom@wg8.so-net.ne.jp

1 **Abstract**

2 *Purpose*

3 We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral
4 density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO)
5 or denosumab (DENO) therapies over 12 months and to determine predictors that establish
6 associations with changes in BMD among the patients received the ROMO therapy.

7 *Methods*

8 Postmenopausal osteoporosis patients with a high risk of fracture—154 in total—were recruited;
9 their therapies were switched to ROMO or DENO from BP/naïve or vitamin D (ND) (ND-
10 ROMO: 43, BP-ROMO: 38, ND-DENO: 38, and BP-DENO: 35). Longitudinal changes in bone
11 metabolic markers and BMD were evaluated.

12 *Results*

13 ROMO groups showed significant increases in BMD of the lumbar spine at 6 and 12 months and
14 femoral neck at 12 months compared to the DENO groups. Although BP-ROMO showed
15 significant increase in the lumbar spine BMD compared to BP-DENO, there were no significant
16 differences in femoral neck and total hip BMDs between BP-ROMO and BP-DENO. Among the
17 ROMO groups, % changes of BMD from baseline to 12 months were associated with bone
18 metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months.

19 *Conclusions*

20 ROMO continuously increased BMD for 12 months and performed better than DENO. On the
21 other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were
22 almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from
23 baseline to 3 months may predict the efficacy of ROMO after 12 months of administration.

1

2 **Keywords:** postmenopausal osteoporosis, romosozumab, denosumab, bone metabolic marker

3

4 **Conflicts of interest/Competing interests**

5 Tomohiro Shimizu, Kosuke Arita, Eihiro Murota, Shigeto Hiratsuka, Ryo Fujita, Tsuyoshi

6 Asano, Masahiko Takahata and Norimasa Iwasaki declare that they have no conflict of interest.

7

1 Introduction

2 Osteoporosis is a chronic, progressive condition that requires long-term management. An
3 estimated 9 million new osteoporosis-related fractures were reported worldwide in the year 2000
4 [1], and 75 million people in the United States, Europe, and Japan are affected by osteoporosis [2].
5 In 2010 there were estimated to be 158 million individuals at high fracture risk. Demographic
6 shifts mean that this figure is likely to double by 2040 [3]. Patients with osteoporosis are usually
7 treated with bisphosphonates (BP) as first-line therapy because of their high effectiveness, long-
8 term benefits, and price considerations. In patients who are at high risk of fractures and patients
9 who do not respond sufficiently, such as those who have a persistent low bone mineral density
10 (BMD) or those who develop fractures regardless of BP therapy, starting or switching to potent
11 therapies is the common clinical practice.

12 Romosozumab (ROMO) is a monoclonal antibody that binds to and inhibits sclerostin.
13 ROMO therapy has a dual effect; it increases bone formation and decreases bone resorption [4,5].
14 Because of this unique dual effect, the anabolic window, which determines the effects of
15 osteoporosis treatment, is assumed to be larger for ROMO than for other osteoporosis treatments
16 [6]. Large-cohort randomized control studies showed that ROMO was associated with increased
17 bone mineral density and formation and decreased bone resorption and lower risk of vertebral
18 fractures than the placebo at 12 months [5,7]. Furthermore, other randomized cohort studies
19 showed that ROMO treatment for 12 months followed by alendronate treatment significantly
20 lowered the risk of fractures than treatment with alendronate and teriparatide [8,9]. Contrarily,
21 there is limited information comparing ROMO with denosumab (DENO), a human monoclonal
22 antibody that targets the osteoclast differentiation factor/receptor activator of the NF-kB ligand
23 [10].

Japan approved ROMO in March 2019 and was the first to do so. Recent clinical reports on Japanese patients with postmenopausal osteoporosis in the real-world setting also showed that ROMO was effective in increasing BMD and preventing fractures even after 4–6 months of treatment [11,12]. Although these reports showed that differences in prior treatment and early changes in bone turnover markers were associated with changes in BMD, there was still a paucity of information regarding the efficacy of ROMO until 12 months and its predictors in the real-world setting. Therefore, the current study aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from BP to ROMO or DENO therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. The hypotheses of this current study were that ROMO therapy could be one of most ideal treatment options for postmenopausal osteoporosis patients with high-risk fragility fracture and that bone metabolic markers before administration could be predictor for the therapeutic efficacy of ROMO.

Materials and Methods

Study design and subjects

This study was conducted in accordance with the ethical standards of the Declaration of Helsinki and approved by the Hokkaido University Hospital Institutional Review Board (#020-0188). A total of 327 patients with postmenopausal osteoporosis met the criteria defined by the Japanese guidelines for prevention and treatment of osteoporosis [13,14], who were at a high risk of fractures, were visited to our clinical team from January 2014 to December 2019. They were treated using DENO (60 mg, subcutaneously every 6 months), zoledronic acid (Zol) (5 mg, intravenous drip infusion), and ROMO (210 mg, subcutaneously every month) in combination

1 with a daily oral active vitamin D by our clinical team from January 2014 to December 2019
2 (Fig. 1). A high risk of fracture was defined by 1) BMD < - 2.5 of SD (standard deviation) and
3 one or more fragility fractures, 2) lumbar BMD < - 3.3 of SD [15,16], 3) two or more fragility
4 fractures [15,17], or 4) semi-quantitative evaluation [18] of existing grade 3 vertebral fracture
5 [17]. The patients were treated with DENO from January 2014 to December 2016, Zol from
6 January 2017 to February 2019, and ROMO from March to December 2019, unless the patients
7 hoped the other therapy. The switch from BPs to the abovementioned treatments showed no
8 increase in BMD. Patients 1) treated with Zol (Zol group); 2) switched from selective estrogen
9 receptor modulator, teriparatide, and DENO (ROMO group); 3) with a history of angina,
10 cerebral, or myocardial infarction; 4) < 50 years old; 5) who were male; and 6) with severe
11 chronic kidney disease (stage 4 and 5), and 7) with abnormal serum levels of albumin-corrected
12 calcium (Ca) (< 8.3 or > 10.3 mg/dL) at baseline, were excluded from the study. Ten of the 112
13 patients treated with ROMO from March to December 2019 dropped out before 12 months—five
14 due to infection with the novel coronavirus, one moved cities, one suffered a cancer recurrence
15 and switched to DENO treatment, and the other three due to unknown reasons. In this current
16 study, we retrospectively investigated 73 patients treated with DENO from January 2014 to
17 December 2016 and 81 patients treated with ROMO from March to December 2019. The
18 following baseline clinical information was obtained: the levels of albumin-corrected Ca, bone
19 metabolic markers, 25-dihydroxy vitamin D [25(OH)D], intact parathyroid hormone (PTH), and
20 liver and renal function from the analysis of blood samples. BMD was evaluated using dual-
21 energy X-ray absorptiometry (DXA); X-rays of the whole spine and full length of the lower
22 limbs were obtained for evaluating previous fragility fractures and risk factors for atypical
23 femoral fractures. The levels of serum albumin-adjusted calcium (Ca), total type I procollagen

N-propeptide (P1NP), and tartrate-resistant acid phosphatase 5b (TRACP 5b) were monitored at 3, 6, and 12 months after starting or switching to ROMO. Monitoring of serum Ca and inflammatory reactions was started after 1 or 2 weeks of DENO and ROMO administration to evaluate changes in Ca levels and assess side effects.

BMD assessment

Areal BMD of the lumbar spine (LS; L2–L4), femoral neck (FN), and total hip (TH) was assessed at baseline and 6 and 12 months after treatment, using Horizon® DXA Bone Densitometer (Hologic Discovery A, Inc., Tokyo, Japan). Regions of severe scoliosis, previous vertebral fracture, and postoperative sites were excluded from BMD measurements; at least two of the L2–L4 lumbar vertebrae had to be evaluated for BMD [19]. Subjects were excluded from the BMD assessment if the area was fractured or operated on during the study.

Statistical analysis

Statistical comparisons between the groups were performed using unpaired *t*-test (durations of pretreatment), or two-way analysis of variance with the Bonferroni test for post hoc comparisons. Spearman's correlation coefficients were calculated, and linear regression models adjusted for age, body mass index (BMI), pretreatment with BPs and active vitamin D, history of fragility fractures, and 25(OH)D levels were established to determine the associations with % changes in BMD between the baseline and 12 months. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS Statistics version 23.0) (IBM Corporation, Armonk, NY, USA) with the significance level set at 0.05.

Results

1 *Clinical characteristics*

2 Table 1 shows the baseline characteristics. The number of patients who switched from
3 naïve or vitamin D to ROMO (ND-ROMO), BPs to ROMO (BP-ROMO), ND to DENO (ND-
4 DENO), and BPs to DENO (BP-DENO) was 43, 38, 38, and 35, respectively. Two-way ANOVA
5 showed statistically significant differences in mean BMI values between treatments (ROMO vs
6 DENO) ($P = 0.016$) and pretreatments (ND vs BP) ($P = 0.031$). No interaction was detected
7 between pretreatment and treatment values ($P = 0.173$). Post hoc Bonferroni tests showed that
8 the mean BMI of patients was significantly higher in the ND-ROMO group than in the BP-
9 ROMO group ($P = 0.019$). The mean duration of pretreatment with BP-DENO was significantly
10 higher than that of pretreatment with BP-ROMO ($P = 0.015$). A total of 21 patients in the ND-
11 ROMO group, 24 in the BP-ROMO group, 10 in the ND-DENO group, and 23 in the BP-DENO
12 group used active vitamin D3. The number of patients who experienced fragility fractures was
13 34, 22, 21, and 23 in the ND-ROMO, BP-ROMO, ND-DENO, and BP-DENO groups,
14 respectively. Two-way ANOVA showed a statistical difference between pretreatments (ND vs
15 BP) in the mean of bone metabolic markers (P1NP: $P < 0.001$ and TRACP-5b: $P < 0.001$). No
16 interaction was detected between pretreatment and treatment values (P1NP: $P = 0.994$ and
17 TRACP-5b: $P = 0.918$). Post hoc Bonferroni tests showed that the mean of bone metabolic
18 markers of patients in the ND-ROMO group was significantly higher than that of those in the
19 BP-ROMO group (P1NP: $P < 0.001$ and TRACP-5b: $P < 0.001$) and that of patients in the ND-
20 DENO group was significantly higher than that of those in the BP-DENO group (P1NP: $P <$
21 0.001 and TRACP-5b: $P < 0.001$). There were no differences in age, Ca levels, estimated
22 glomerular filtration rate (eGFR) levels, 25(OH)D levels, intact PTH level, and percent young
23 adult mean (% YAM) at baseline, between the groups. Notably, one patient each in the BP-

ROMO experienced the right calcaneus fracture at 6 months after administration. One patient in the ND-DENO group and two patients in the BP-DENO group were observed the occurrence of new vertebral body fracture at 12 months after administration.

Longitudinal changes in Ca, P1NP, and TRACP 5b levels

For the decrease in serum Ca levels from baseline to 1 or 2 weeks, two-way ANOVA showed a statistically significant difference between pretreatments (ND vs BP) ($P = 0.031$). No interaction was detected between the pretreatment and treatment values ($P = 0.485$). Post hoc Bonferroni tests did not show significant differences between ND and BP in the ROMO and DENO groups (ROMO: $P = 0.491$ and DENO: $P = 0.093$). While no patients showed hypocalcaemia (Ca level < 8.4) in the ROMO group, three patients in the ND-ROMO group showed hypocalcaemia. However, none experienced serious side effects related to it (tonic convulsions and tetany).

For the change of P1NP levels at 3, 6, and 12 months, two-way ANOVA showed statistically significant differences between pretreatments (ND vs BP) (3 months: $P = 0.003$, 6 months: $P < 0.001$, and 12 months: $P < 0.001$) and treatments (ROMO vs DMAb) (3 months: $P < 0.001$, 6 months: $P < 0.001$, and 12 months: $P < 0.001$) (Fig. 2a). There were significant interactions between pretreatment and treatment values at 6 and 12 months (6 months: $P = 0.026$ and 12 months: $P = 0.009$). For the change of TRACP-5b levels at 3, 6, and 12 months, two-way ANOVA showed statistically significant differences between pretreatments (ND vs BP) (3 months: $P < 0.003$, 6 months: $P = 0.001$, and 12 months: $P < 0.001$) and treatments (ROMO vs DENO) (3 months: $P < 0.001$, 6 months: $P < 0.001$, and 12 months: $P < 0.001$) (Fig. 2b). No interaction was detected between the pretreatment and treatment values.

Longitudinal changes in BMD

At 6 and 12 months after the administration of ROMO or DENO, all groups showed increases in lumbar spine, femoral neck, and total hip BMDs compared to those at baseline (Fig. 3). For the change in BMD of the lumbar spine at 6 and 12 months, two-way ANOVA showed a statistically significant difference between treatments (ROMO vs DENO) (6 months: $P < 0.001$ and 12 months: $P < 0.001$) (Fig. 3a). No interaction was detected between the pretreatment and treatment values. For the change in BMD of the femoral neck at 6 months, two-way ANOVA showed a statistically significant difference between pretreatments (ND vs BP) ($P = 0.031$) (Fig. 3b). For that at 12 months, two-way ANOVA showed a statistically significant difference between treatments (ROMO vs DENO) ($P = 0.041$). No interaction was detected between the pretreatment and treatment values. For the change in BMD of the total hip at 6 months, two-way ANOVA showed a statistically significant difference between pretreatments (ND vs BP) (6 months: $P = 0.027$ and 12 months: $P = 0.006$) (Fig. 3c). There was a significant interaction between pretreatment and 12-month treatment values of BMDs of the total hip ($P = 0.021$).

Association between change in BMD from baseline to 12 months in the ROMO groups

Spearman's correlation coefficients revealed that the significant confounders ($P < 0.05$) for the BMD change of the lumbar spine at 12 months were age ($r = -0.283$, $P = 0.021$), BMI ($r = -0.273$, $P = 0.035$), P1NP value at baseline ($r = 0.389$, $P = 0.001$), TRACP-5b value at baseline ($r = 0.401$, $P < 0.001$) and its percentage change at three months ($r = -0.326$, $P = 0.024$), and 25 OHD value at baseline ($r = 0.271$, $P = 0.029$). The significant confounders for the BMD change of the femoral neck at 12 months were age ($r = -0.410$, $P = 0.002$), P1NP value at baseline ($r = 0.310$, $P = 0.025$), and TRACP-5b value at baseline ($r = 0.359$, $P = 0.009$) and its percentage change at three months ($r = -0.295$, $P = 0.044$). The significant confounders for the BMD change

of the total hip at 12 months were P1NP value at baseline ($r = 0.494$, $P < 0.001$) and its percentage change at three months ($r = -0.331$, $P = 0.025$), and TRACP-5b value at baseline ($r = 0.489$, $P < 0.001$) and its percentage change at three months ($r = -0.329$, $P = 0.025$).

In the linear regression models adjusted for age, body mass index (BMI), pretreatment with BPs and active vitamin D, history of fragility fractures, and 25(OH)D levels, the % changes of BMD of the lumbar spine from baseline to 12 months were associated with P1NP value at baseline ($\beta = 0.439$, $P = 0.003$), and TRACP-5b value at baseline ($\beta = 0.576$, $P < 0.001$) and its percentage change at three months ($\beta = -0.528$, $P = 0.003$) (Table 2). Percentage changes of BMD of the femoral neck from baseline to 12 months were associated with P1NP ($\beta = 0.343$, $P = 0.049$) and TRACP-5b ($\beta = 0.467$, $P = 0.015$) values at baseline. Percentage changes of BMD of the total hip from baseline to 12 months were associated with P1NP value at baseline ($\beta = 0.434$, $P = 0.003$), and TRACP-5b value at baseline ($\beta = 0.329$, $P = 0.037$) and its percentage change at three months ($\beta = -0.407$, $P = 0.029$).

Discussion

This study investigated the longitudinal efficacy of ROMO over 12 months, the maximum period approved for insurance practice in Japan, in a real-world setting. It showed that ROMO increased the BMDs of the lumbar spine, femoral neck, and total hip at 12 months. This finding was consistent with that of a previous clinical trial [20-22] and a 6-month-observational study in a real-world setting [11,12] on Japanese patients with postmenopausal osteoporosis. Considering that the ND-ROMO and BP-ROMO groups showed increases in BMDs of the lumbar spine, femoral neck, and total hip from 6 to 12 months regardless of the decrease in dual effect, increase in bone formation, and decrease in bone resorption [4,5], continuous

administration of ROMO for 12 months could potentially increase BMD.

Consistent with previous reports [11,23], we found that the bone metabolic markers at baseline were associated with changes in BMD over 12 months in patients treated with ROMO. Therefore, bone metabolic markers at baseline are useful predictors of BMD during ROMO treatment. This finding suggested that pretreatment with bisphosphonate decreased the increase of BMD with ROMO. Contrary to other clinical observations [12], this study did not show any association between early changes in P1NP and changes in BMD at 12 months. However, we observed that early changes in TRACP-5b were associated with changes in BMD at 12 months. This discrepancy may be attributed to the current study evaluating only the three months change and not the one month change as previously described [12]. Considering that ROMO was associated with a transient increase in bone formation markers and sustained decrease in bone-resorption markers [5], earlier changes in bone metabolic markers, such as in one month, might be more appropriate for predicting changes in BMD.

This study showed that ROMO significantly increased the lumbar spine and femoral neck BMD at 12 months compared to DENO. Therefore, ROMO is more effective in increasing BMD than DENO, alendronate, and teriparatide; this finding is in line with results shown in a phase 2, multicentre, international, and randomized control study [5]. On the other hand, this study also showed that the effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Therefore, 12 months ROMO treatment may not be a more ideal and sufficient treatment for patients with low BMD of femoral neck or total hip who received BP therapy previously. To the best of our knowledge, this is the first study that compares the efficacy of ROMO and DENO in postmenopausal osteoporosis patients with a high risk of fracture. Because the characteristics of patients recruited varied with time, the comparison

1 between ROMO and DENO may not be accurate; this is the main limitation of this study.
2 Therefore, a randomized control comparison study is warranted in the future to confirm the
3 superiority of ROMO over DENO.

4 The FRAME trial showed that BMD continued to increase after switching from ROMO
5 to DENO [7], and Ebina et al. showed that pretreatment for bone resorption attenuated the
6 increase of BMD in ROMO compared to that in the control group [11]. Additionally, Kashii et
7 al. showed that ROMO is not effective in preventing vertebral fractures or multiple spontaneous
8 clinical vertebral fractures after DENO discontinuation [24]. Therefore, it might be better for
9 postmenopausal patients with a high risk of fracture to be treated first with ROMO rather than
10 with bone resorption inhibitors. Comparison studies in the future should address this speculation
11 to establish a therapeutic strategy for osteoporosis with a high risk of fracture.

12 This study has some limitations. First, the study had a small sample size. Therefore, the
13 statistical power of the results might be attenuated, and the fracture occurrence rate after
14 initiation of treatment might be underestimated. Second, this study included pretreatment with
15 various BPs, including alendronate and risedronate, and active vitamin D3, such as alfacalcidol
16 and ELD, which might have affected the results. Because this was not a randomized study,
17 differences in patients' backgrounds may potentially affect the physicians' treatment selection
18 and subsequent effects. Larger randomized studies with longer follow-up periods should be
19 conducted in the future.

20 In conclusion, in this 12-month follow-up study of postmenopausal osteoporosis patients
21 with a high risk of fracture who were introduced to ROMO or DENO in a real-world setting,
22 ROMO continuously increased BMD for 12 months and performed better than DENO. On the
23 other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were

almost same with DENO. For patients treated by ROMO, bone metabolic markers at baseline and changes in TRACP-5b levels from the baseline to 3 months were associated with changes in BMD from baseline to 12 months. These findings suggest that these parameters could be useful in predicting the efficacy of ROMO. Although these results may contribute to establishing a therapeutic strategy for osteoporosis with a high risk of fracture, further investigations are required.

Acknowledgements

This study was funded by Grant-in-Aid for Young Scientists from the Ministry of Education, Culture, Sports, Science, and Technology of Japan 20K17948 (T. Shimizu).

1 **References**

- 2 1. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability
3 associated with osteoporotic fractures. *Osteoporos Int* 17:1726-33 doi:10.1007/s00198-006-
4 0172-4
- 5 2. Who are candidates for prevention and treatment for osteoporosis? (1997). *Osteoporos*
6 *Int* 7:1-6
- 7 3. Oden A, McCloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high
8 fracture probability worldwide: secular increases 2010-2040. *Osteoporos Int* 26:2243-8
9 doi:10.1007/s00198-015-3154-6
- 10 4. Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled,
11 randomized study of AMG 785, a sclerostin monoclonal antibody. *J Bone Miner Res* 26:19-26
12 doi:10.1002/jbmr.173
- 13 5. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl
14 BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone
15 HG (2014) Romosozumab in postmenopausal women with low bone mineral density. *N Engl J*
16 *Med* 370:412-20 doi:10.1056/NEJMoa1305224
- 17 6. Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D (2016) Treatment needs and
18 current options for postmenopausal osteoporosis. *Expert Opin Pharmacother* 17:1141-52
19 doi:10.1080/14656566.2016.1176147
- 20 7. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer
21 LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner
22 PD, Libanati C, Grauer A (2016) Romosozumab Treatment in Postmenopausal Women with
23 Osteoporosis. *N Engl J Med* 375:1532-43 doi:10.1056/NEJMoa1607948

- 1 8. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J,
2 Fan M, Meisner PD, Grauer A (2017) Romosozumab or Alendronate for Fracture Prevention in
3 Women with Osteoporosis. *N Engl J Med* 377:1417-27 doi:10.1056/NEJMoa1708322
- 4 9. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al. (2017)
5 Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women
6 with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label,
7 phase 3 trial. *Lancet* 390:1585-94 doi:10.1016/S0140-6736(17)31613-6
- 8 10. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San
9 Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway
10 and the development of denosumab. *Nat Rev Drug Discov* 11:401-19 doi:10.1038/nrd3705
- 11 11. Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya
12 H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A, Nakata K (2020) Effects of prior
13 osteoporosis treatment on early treatment response of romosozumab in patients with
14 postmenopausal osteoporosis. *Bone* 140:115574 doi:10.1016/j.bone.2020.115574
- 15 12. Tominaga A, Wada K, Kato Y, Nishi H, Terayama Y, Okazaki K (2020) Early clinical
16 effects, safety, and appropriate selection of bone markers in romosozumab treatment for
17 osteoporosis patients: a 6-month study. *Osteoporos Int* doi:10.1007/s00198-020-05639-y
- 18 13. Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M,
19 Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012)
20 Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary.
21 *Arch Osteoporos* 7:3-20 doi:10.1007/s11657-012-0109-9
- 22 14. Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M,
23 Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for B, Mineral R, Japan

- 1 Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for
2 Primary O (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner
3 Metab 31:247-57 doi:10.1007/s00774-013-0447-8
- 4 15. Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide
5 is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in
6 postmenopausal women with osteoporosis. J Bone Miner Res 18:18-23
7 doi:10.1359/jbmr.2003.18.1.18
- 8 16. Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K et al. (2011) Design of a
9 pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of
10 osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention
11 Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP).
12 J Bone Miner Metab 29:37-43 doi:10.1007/s00774-010-0188-x
- 13 17. Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces
14 the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin
15 Endocrinol Metab 90:1583-7 doi:10.1210/jc.2004-0826
- 16 18. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment
17 using a semiquantitative technique. J Bone Miner Res 8:1137-48 doi:10.1002/jbmr.5650080915
- 18 19. Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2015)
19 Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA
20 patients: response to Mokuda. Osteoporos Int 26:1445 doi:10.1007/s00198-014-2993-x
- 21 20. Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer
22 A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women
23 with osteoporosis: A phase 2 study. Bone 103:209-15 doi:10.1016/j.bone.2017.07.005

21. Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J (2019) Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14:59 doi:10.1007/s11657-019-0608-z
22. Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J (2020) Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab doi:10.1007/s00774-020-01147-5
23. Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hiramata T, Libanati C, Nakamura Y, Milmont CE, Grauer A (2020) Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. J Bone Miner Metab 38:310-15 doi:10.1007/s00774-019-01057-1
24. Kashii M, Ebina K, Kitaguchi K, Yoshikawa H (2020) Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report. Bone Rep 13:100288 doi:10.1016/j.bonr.2020.100288

1 Table 1 Clinical characteristics at baseline

Variable	Romosozumab		Denosumab	
	ND	BPs	ND	BPs
Number	43	38	38	35
Age, years	75.3 (1.2)	73.7 (1.7)	71.8 (1.4)	74.4 (1.5)
BMI ^{*,†} , kg/m ²	22.1 (0.6)	20.0 (0.6)	22.7 (0.5)	22.2 (0.6)
Duration of pretreatment [*] , months	NA	26.2 (3.9)	NA	43.8 (5.9)
Prior active vitamin D3 use	21 patients	24 patients	10 patients	23 patients
History of fragility fractures	34 patients	22 patients	21 patients	23 patients
Ca, mg/dL	9.51 (0.08)	9.56 (0.09)	9.47 (0.06)	9.58 (0.07)
eGFR, mL/min/1.73mm ²	65.8 (2.4)	68.4 (2.7)	73.4 (2.3)	69.2 (3.2)
P1NP [†] , ng/mL	62.7 (5.9)	30.2 (4.6)	56.3 (5.4)	21.6 (2.0)
TRACP-5b [†] , mU/dL	497.6 (37.2)	285.5 (28.5)	451.0 (27.2)	279.5 (20.2)
25(OH)D, ng/mL	15.3 (0.8)	17.5 (0.9)	17.7 (1.0)	17.0 (1.2)
Intact PTH, pg/mL	42.2 (3.4)	32.8 (4.1)	37.1 (1.1)	36.8 (2.4)
%YAM Lumbar, %	71.5 (1.9)	68.2 (2.7)	68.5 (2.1)	71.7 (2.1)
%YAM FN, %	62.5 (2.0)	62.1 (1.6)	61.8 (1.6)	62.2 (1.6)
%YAM TH, %	69.6 (2.2)	67.5 (1.8)	68.0 (1.7)	65.9 (1.9)

2 Mean (standard error of the mean). *: P < 0.05 romosozumab vs. denosumab, †: P < 0.05 ND vs.

3 BP group.

4 ND: naïve or vitamin D, BPs: bisphosphonates, BMI: body mass index, Ca: calcium, Cr:

5 creatinine, eGFR: estimated glomerular filtration rate, P1NP: total type 1 procollagen-N-

6 propeptide, TRACP-5b: tartrate-resistant acid phosphatase 5b, 25(OH)D: 25-hydroxy vitamin D,

7 PTH: parathyroid hormone, YAM: young adult mean, FN: femoral neck, TH: total hip

8

9

10

Table 2 Linear regression models of association of changes in bone mineral density among patients treated by Romosozumab

Factor	β	95 % confidence interval		P-value
% change of BMD of the lumbar spine				
P1NP at BL	0.439	0.029	0.134	0.003
TRACP-5b at BL	0.576	0.010	0.029	<0.001
% change of P1NP at 3M	-0.136	-0.033	0.014	0.422
% change of TRACP-5b at 3M	-0.528	-0.213	-0.047	0.003
% change of BMD of the femoral neck				
P1NP at BL	0.343	0.001	0.209	0.049
TRACP-5b at BL	0.467	0.006	0.048	0.015
% change of P1NP at 3M	0.090	-0.030	0.050	0.621
% change of TRACP-5b at 3M	-0.160	-0.216	0.093	0.424
% change of BMD of the total hip				
P1NP at BL	0.434	0.029	0.139	0.003
TRACP-5b at BL	0.329	0.008	0.024	0.037
% change of P1NP at 3M	-0.079	-0.030	0.019	0.659
% change of TRACP-5b at 3M	-0.407	-0.190	-0.011	0.029

#Adjusted by age, body mass index, pretreatment with BPs and active vitamin D, history of fragility fractures, and 25(OH)D levels. P1NP: total type 1 procollagen-N-propeptide, TRACP-5b: tartrate-resistant acid phosphatase 5b, 25(OH)D: 25-hydroxy vitamin D, BL: baseline, and 3M: 3 months.

1 **Figure legends**


2 **Fig. 1** Study design. SERM: selective estrogen receptor modulator.

3 **Fig. 2** Comparison of longitudinal changes in (a) serum P1NP and (b) serum TRACP-5b levels at
4 3-, 6-, and 12-months post-administration. Data show mean $\pm$ standard error of the mean, *P <
5 0.05: Romosozumab vs. Denosumab, †P<0.05: non-bisphosphonate vs. bisphosphonate.
6 #P<0.05, interaction. BP: bisphosphonates, P1NP: total type 1 procollagen-N-propeptide,
7 TRACP-5b: tartrate-resistant acid phosphatase 5b.

8 **Fig. 3** Longitudinal % changes in bone mineral densities of the (a) lumbar, (b) femoral neck, and
9 (c) total hip. Data show mean $\pm$ standard error of the mean. *P < 0.05: Romosozumab vs.
10 Denosumab, †P<0.05: non-bisphosphonate vs. bisphosphonate. BP: bisphosphonate. BMD: bone
11 mineral density.

12


Postmenopausal osteoporosis with high risk of fracture N=327



a


Change of P1NP, %



- Romosozumab switched from naïve or vitamin D (N=43)
- Romosozumab switched from BP (N=38)
- Denosumab switched from naïve or vitamin D (N=38)
- Denosumumab switched from BP (N=35)

**b**

Change of TRACP-5b, %

- Romosozumab switched from naïve or vitamin D (N=43)
- Romosozumab switched from BP (N=38)
- Denosumab switched from naïve or vitamin D (N=38)
- Denosumab switched from BP (N=35)



a**b****c**